Loading...
•
Dec 31, 2020
Novavax Q4 2020 Earnings Report
Announced fourth quarter and full year 2020 financial results and operational highlights.
Key Takeaways
Novavax reported a net loss of $177.6 million, or $2.70 per share, for the fourth quarter of 2020. Novavax revenue in the fourth quarter of 2020 was $279.7 million.
Novavax continues to make significant strides towards bringing NVX-CoV2373, their COVID-19 vaccine candidate, to market.
NVX-CoV2373 offers a highly unique profile, including the ability to ship and store the vaccine at traditional refrigerated temperatures.
Novavax has secured agreements for the delivery of approximately 300 million doses of NVX-CoV2373.
Novavax is partnering with the Serum Institute of India to jointly supply 1.1 billion doses of NVX-CoV2373 to Gavi through the COVAX Facility.
Forward Guidance
Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...